by Vandana Singh | Sep 22, 2026 | General
Celldex Therapeutics Inc. (NASDAQ:CLDX) on Tuesday shared topline results from its Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 clinical trials. The studies evaluate barzolvolimab for patients with chronic spontaneous urticaria (CSU) who experience inadequate symptom control...
by Kaustubh Bagalkote | Sep 22, 2026 | General
Carnival Corporation Ltd. (NYSE:CCL) stock is surging on Tuesday, primarily driven by ebbing crude oil prices and a broader market sector rally for airline and travel stocks. The Nasdaq is up 0.26% while the S&P 500 is flat and Consumer Discretionary is leading...
by Benzinga Insights | Sep 22, 2026 | General
First Citizens BancShares (NASDAQ:FCNCA) has outperformed the market over the past 5 years by 7.23% on an annualized basis producing an average annual return of 19.03%. Currently, First Citizens BancShares has a market capitalization of $23.96 billion. Buying $100 In...
by Daragh Thomas | Sep 22, 2026 | General
Olas unveiled a new AI model Tuesday that was trained on more than 200,000 prediction market forecasts and matched OpenAI’s GPT-4.1 in a test of its ability to predict real-world events. Olas-Predict-R1-14B achieved 75.8% accuracy across 2,628 previously unseen...
by Vandana Singh | Sep 22, 2026 | General
Ionis Pharmaceuticals Inc. (NASDAQ:IONS) and Otsuka on Tuesday shared positive topline results from their Phase 3 FUSION trial. The trial evaluated ulefnersen, an investigational RNA-targeted medicine, in patients with amyotrophic lateral sclerosis (ALS) caused by...
Recent Comments